Related Experiment Videos
Detection of residual leukemia with immunologic methods: technical developments and clinical implications
D Campana1, R O Freitas, E Coustan-Smith
1Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101.
Leukemia & Lymphoma
|January 1, 1994
Summary
Identifying unique immunophenotypes on leukemia cells aids in monitoring minimal residual disease. These markers are crucial for detecting leukemia recurrence early in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Monitoring minimal residual disease (MRD) in leukemia is crucial for treatment efficacy.
- Immunophenotypes unique to leukemic cells offer a means to detect rare cancer cells amidst normal hematopoiesis.
Purpose of the Study:
- To evaluate the utility of immunophenotypic analysis for detecting MRD in acute leukemias.
- To assess the potential for identifying new leukemia-associated phenotypes to improve detection rates.
Main Methods:
- Analysis of immunophenotypes expressed on leukemic cells but absent in normal hematopoiesis.
- Utilizing flow cytometry for detection of residual disease at a sensitivity of 1 leukemic cell in 10,000 normal cells.
Main Results:
- Specific immunophenotypes enable MRD detection in 90% of T-lineage acute lymphoblastic leukemia (T-ALL), 25% of B-lineage ALL, and 40% of acute myeloid leukemia (AML) cases.
- Detection of MRD using immunologic techniques often predicts overt relapse in acute leukemia patients.
Conclusions:
- Immunophenotypic analysis is a reliable method for monitoring MRD in acute leukemia.
- Further research is needed to define the clinical significance of MRD detection timing and to expand the range of detectable leukemia-associated phenotypes through new techniques and antibodies.